-
公开(公告)号：US20170218451A1
公开(公告)日：2017-08-03
申请号：US15486788
申请日：2017-04-13
申请人： HIROTAKA MATSUO , NARIYOSHI SHINOMIYA , TAKAHIRO NAKAMURA , THE UNIVERSITY OF TOKYO , TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES
发明人： HIROTAKA MATSUO , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： Methods of treating, or at least inhibiting the onset of, urate transport failure are provided. The methods can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
-
2.发明申请METHOD FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR 审中-公开评估尿酸运输相关疾病因子和与炎症相关疾病因子的方法公开(公告)号：US20150080257A1
公开(公告)日：2015-03-19
申请号：US14542633
申请日：2014-11-16
申请人： HIROTAKA MATSUO , NARIYOSHI SHINOMIYA , TAKAHIRO NAKAMURA , THE UNIVERSITY OF TOKYO , TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES
发明人： HIROTAKA MATSUO , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F2085, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译： 提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。 该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。 当受试者具有V12M，R113X，Q126X，Q141K，F2085，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够 诱导尿酸盐运输失败，或归因于该失败的状态或疾病。 当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化， 所述变异与其他SNP的连锁不平衡有关。
-
3.发明授权Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug 有权尿酸转运蛋白，以及评估尿酸运输相关疾病因子和炎症相关疾病因子的方法和试剂盒，以及测试样品和药物公开(公告)号：US08940286B2
公开(公告)日：2015-01-27
申请号：US13379346
申请日：2010-06-22
申请人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
发明人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
IPC分类号： A61K48/00 , A61K38/00 , C07K14/47 , C07K14/705 , G01N33/566 , G01N33/68
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译： 提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。 该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。 当受试者具有V12M，R113X，Q126X，Q141K，F208S，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够 诱导尿酸盐运输失败，或归因于该失败的状态或疾病。 当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化， 所述变异与其他SNP的连锁不平衡有关。
-
4.发明申请URATE TRANSPORTER, AS WELL AS METHOD AND KIT FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR, AND TEST SAMPLE AND DRUG 有权URATE TRANSPORTER，作为评估与运输相关的疾病因素和与炎症有关的疾病因素和测试样品和药物的方法和工具包公开(公告)号：US20120255044A1
公开(公告)日：2012-10-04
申请号：US13379346
申请日：2010-06-22
申请人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
发明人： Hirotaka Matsuo , Nariyoshi Shinomiya , Takahiro Nakamura , Tappei Takada , Hiroshi Suzuki , Yuki Ikebuchi , Kousei Ito , Kimiyoshi Ichida
CPC分类号： C12Q1/6883 , A61K38/177 , C07K14/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/566 , G01N33/6893 , G01N2800/24 , G01N2800/32 , G01N2800/34
摘要： A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.
摘要翻译： 提供了一种方法和评价试剂盒，其中确定了高容量尿酸转运蛋白，以协助早期治疗和预防与尿酸运输有关的疾病和炎症相关疾病。 该方法可以包括用于检测编码ABCG2蛋白的基因变异的步骤。 当受试者具有V12M，R113X，Q126X，Q141K，F208S，G268R，E334X，S441N，L447V，S486N，F506SfsX4，R575X和/或C608X的SNP时，可以得出结论，受试者具有能够 诱导尿酸盐运输失败，或归因于该失败的状态或疾病。 当受试者具有V12M的SNP时，可以得出结论，与其他SNP不同，存在受试者不具有这样的因素的可能性，因为尽管该变化本身不会导致尿酸盐转运能力的变化， 所述变异与其他SNP的连锁不平衡有关。
-
5.发明申请MOLECULE ASSOCIATED WITH ONSET OF GOUT, AND METHOD AND KIT FOR EVALUATING DIATHESIS OF URIC ACID-RELATED DISEASES AND INFLAMMATION-RELATED DISEASES, AND INSPECTION OBJECT AND DRUG 审中-公开与GOUT相关的分子，以及用于评估尿酸相关性疾病和相关疾病的诊断的方法和工具，以及检查对象和药物公开(公告)号：US20170002413A1
公开(公告)日：2017-01-05
申请号：US15112067
申请日：2015-01-19
CPC分类号： C12Q1/6883 , A61K38/00 , A61K38/1709 , A61K38/177 , A61K38/44 , A61K38/45 , A61K38/53 , A61K48/00 , C07K14/47 , C12N9/00 , C12Q2600/156 , C12Y102/01003 , C12Y207/11025 , C12Y603/04 , G01N33/6893 , G01N2800/107
摘要： To specify a molecule associated with the onset of gout so as to provide a method for evaluating a diathesis of uric acid-related diseases and a diathesis of inflammation-related diseases, an evaluation kit for carrying out the method, an inspection object, and a drug, on the basis of the molecule specified above, for contributing to the early treatment and prevention of the uric acid-related diseases and inflammation-related diseases. The molecule includes any one protein and cDNA of CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, MAP3K11, NPT4, ABCG2, HIST1H2BF/HIST1H4E, HIST1H2BE/HIST1H4D and FAM35A, or proteins of combination thereof with GLUT9, NPT1, URAT1, or NXRN2, and is capable of selectively inducing gout. A molecule includes protein and cDNA of an ABCG2 variant and is capable of selectively and ATP-dependently decreasing urate excretion.
摘要翻译： 为了指定与痛风发作相关的分子，以提供评估尿酸相关疾病的素质和炎症相关疾病的素质的方法，用于实施该方法的评估套件，检查对象和 药物，基于上述分子，有助于早期治疗和预防尿酸相关疾病和炎症相关疾病。 该分子包括CNIH2-PACS1，ALDH2，MYL2-CUX2，GCKR，MAP3K11，NPT4，ABCG2，HIST1H2BF / HIST1H4E，HIST1H2BE / HIST1H4D和FAM35A的任何一种蛋白质和cDNA，或与GLUT9，NPT1，URAT1或 NXRN2，能够选择性地诱发痛风。 分子包括ABCG2变体的蛋白质和cDNA，并且能够选择性地和ATP依赖性地减少尿酸排泄。
-
公开(公告)号：US11098364B2
公开(公告)日：2021-08-24
申请号：US16405812
申请日：2019-05-07
IPC分类号： C12Q1/68 , C12P19/34 , C12Q1/6883 , A61K38/00 , C07K14/47 , G01N33/68 , A61K38/17 , A61K38/44 , A61K38/45 , A61K38/53 , C12N9/00 , A61K48/00
摘要： To specify a molecule associated with the onset of gout so as to provide a method for evaluating a diathesis of uric acid-related diseases and a diathesis of inflammation-related diseases, an evaluation kit for carrying out the method, an inspection object, and a drug, on the basis of the molecule specified above, for contributing to the early treatment and prevention of the uric acid-related diseases and inflammation-related diseases. The molecule includes any one protein and cDNA of CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, MAP3K11, NPT4, ABCG2, HIST1H2BF/HIST1H4E, HIST1H2BE/HIST1H4D and FAM35A, or proteins of combination thereof with GLUT9, NPT1, URAT1, or NXRN2, and is capable of selectively inducing gout. A molecule includes protein and cDNA of an ABCG2 variant and is capable of selectively and ATP-dependently decreasing urate excretion.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.029 秒)
